The weekly litigation news digest is live. Subscribe now

IP Verse

Mitsubishi Tanabe Pharma competitive analysis

Loading summary...

Latest patents of Mitsubishi Tanabe Pharma opposed by its competitors

Explore Mitsubishi Tanabe Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 20, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3875085
Jun 19, 2024Edaravone Suspension For Oral Administration1
EP2896397
Oct 7, 2020Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter2
EP2252289
Oct 23, 2019Combination Therapy Comprising Sglt Inhibitors And Dpp4 Inhibitors1
EP2754440
Apr 3, 2019Medicinal Agent For Treating Amyotrophic Lateral Sclerosis Or Preventing Progression Of Phase Of Amyotrophic Lateral Sclerosis1
EP1714960
Mar 28, 2018Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) Or Disease Attributable To Als1

Latest PTAB cases involving Mitsubishi Tanabe Pharma

Discover the latest PTAB cases involving Mitsubishi Tanabe Pharma, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Mitsubishi Tanabe Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 20, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
MITSUBISHI TANABE PHARMA - 6 - -
ELKINGTON AND FIFE92 - - -
GALENICUM HEALTH SL113 - -
MAIWALD136 - - -